Richmond Pharmacology is a leading contract research organization (CRO) specialising in early-phase clinical trials. Richmond Pharmacology was founded in 2001 through a partnership with the NHS and St George’s University Hospital, London, United Kingdom.

We specialise in first-in-human studies and adaptive clinical trials, conducting 20% of the overall number of Phase I studies in the UK. The first patient in the first ever in vivo CRISPR-cas9 FIH study was treated by us. We are one of the leaders in advanced therapy studies.

Our clients are international with trial sponsors coming from Europe, US and Japanese markets.

As a research organisation run by healthcare professionals, Richmond Pharmacology makes a meaningful contribution towards bringing new medicines to market. We interact with healthy research volunteers, patients, clinical and academic specialists in their respective fields, to ensure our research meets the highest regulatory, scientific, quality, and ethical standards. We are personable, flexible, and transparent in our processes.

How do we do this?

Richmond’s long-established partnership with a world-class Scientific Advisory Board provides medically driven outcome-based solutions and puts us at the forefront of the industry globally.

Our accreditation by the Medicines and Healthcare Products Regulatory Agency provides assurance that you will be working with a credible organisation that conforms to only the highest of clinical and regulatory standards.